Log In
BCIQ
Print this Print this
 

BCL2 inhibitor

  Manage Alerts
Collapse Summary General Information
Company Vernalis plc
DescriptionB cell lymphoma 2 (BCL-2; BCL2) inhibitor
Molecular Target B cell lymphoma 2 (BCL-2) (BCL2)
Mechanism of ActionBcl-2 inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
PartnerServier

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/19/2014

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today